Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has received an average recommendation of “Moderate Buy” from the eleven research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $32.3750.

CNTA has been the subject of a number of research analyst reports. Wells Fargo & Company assumed coverage on shares of Centessa Pharmaceuticals in a report on Wednesday, September 3rd. They issued an “overweight” rating and a $31.00 price target for the company. Truist Financial initiated coverage on shares of Centessa Pharmaceuticals in a report on Monday, July 21st. They issued a “buy” rating and a $30.00 target price for the company. Wall Street Zen downgraded shares of Centessa Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Saturday, September 27th. Finally, Lifesci Capital raised Centessa Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, September 3rd.

Insider Buying and Selling at Centessa Pharmaceuticals

In related news, insider Mario Alberto Accardi sold 8,322 shares of the stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $15.23, for a total value of $126,744.06. Following the sale, the insider directly owned 208,163 shares of the company’s stock, valued at approximately $3,170,322.49. This represents a 3.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CTO Tia L. Bush sold 35,000 shares of the firm’s stock in a transaction dated Wednesday, September 24th. The shares were sold at an average price of $24.00, for a total transaction of $840,000.00. Following the transaction, the chief technology officer owned 121,503 shares of the company’s stock, valued at $2,916,072. This trade represents a 22.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 205,286 shares of company stock worth $3,993,345. Insiders own 7.09% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Ameriprise Financial Inc. acquired a new stake in shares of Centessa Pharmaceuticals during the fourth quarter valued at $320,000. Squarepoint Ops LLC lifted its stake in shares of Centessa Pharmaceuticals by 33.2% during the fourth quarter. Squarepoint Ops LLC now owns 26,806 shares of the company’s stock valued at $449,000 after buying an additional 6,685 shares during the period. Wellington Management Group LLP boosted its position in Centessa Pharmaceuticals by 14.4% during the fourth quarter. Wellington Management Group LLP now owns 115,107 shares of the company’s stock worth $1,928,000 after acquiring an additional 14,494 shares during the last quarter. GAMMA Investing LLC raised its holdings in Centessa Pharmaceuticals by 1,509.6% in the 1st quarter. GAMMA Investing LLC now owns 61,762 shares of the company’s stock valued at $888,000 after acquiring an additional 57,925 shares during the last quarter. Finally, HighMark Wealth Management LLC lifted its stake in shares of Centessa Pharmaceuticals by 41.9% during the 1st quarter. HighMark Wealth Management LLC now owns 235,785 shares of the company’s stock worth $3,391,000 after purchasing an additional 69,650 shares during the period. 82.01% of the stock is owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $23.23 on Monday. The company has a current ratio of 10.11, a quick ratio of 10.12 and a debt-to-equity ratio of 0.32. The stock has a 50 day simple moving average of $19.12 and a 200-day simple moving average of $15.33. The company has a market cap of $3.11 billion, a price-to-earnings ratio of -12.98 and a beta of 1.57. Centessa Pharmaceuticals has a 12-month low of $9.60 and a 12-month high of $24.57.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). On average, equities analysts forecast that Centessa Pharmaceuticals will post -1.6 EPS for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.